⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 27, 2023Research and Practice in Thrombosis and HaemostasisOpen Access

Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China

View Full Paper

Ask AI

Bookmark

Share

Authors

HMHeng MeiUnion Hospital HZHu ZhouUniversity of Nottingham Ningbo China MHMing HouShandong University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mei et al. (2023) studied this question.

synapsesocial.com/papers/6a82e6f757df60cfb510c667 https://doi.org/10.1016/j.rpth.2023.102158

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Transitioning patients with immune thrombocytopenia to second‐line therapy: Challenges and best practices2018 · 54 citations
2International consensus report on the investigation and management of primary immune thrombocytopenia2009 · 2,281 citations
3Updated international consensus report on the investigation and management of primary immune thrombocytopenia2019 · 1,156 citations
4A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia2021 · 74 citations
5Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study2022 · 13 citations